FDA Orange Book · active-ingredient family
Amifostine
Amifostine is approved as 1 brand and 2 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:ETHYOL · NDA 020221
1
Brand (NDA)
2
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ETHYOLRLD×2 | LEGACY PHARMA | NDA 020221 | — | Dec 08, 1995 |
Generic (ANDA) products (2)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| AMIFOSTINE | EUGIA PHARMA SPECLTS | ANDA 204363 | — | Jul 17, 2017 | |
| AMIFOSTINE | SUN PHARM | ANDA 077126 | — | Mar 14, 2008 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Amifostine — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

